24715

    544222

    AKUMS

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    AKUMS DRUGS AND PHARMA L Share Price Today

    AKUMS DRUGS AND PHARMA L is currently trading at ₹674.65, down by ₹12.64 from the previous close. The stock touched an intraday high of ₹703.00 and a low of ₹673.70 during the latest trading session. Over the past one year, AKUMS DRUGS AND PHARMA L has delivered a return of 27.89%, while the stock has gained 12.01% in the last one month.

    AKUMS DRUGS AND PHARMA L performance

    Today’s low Today’s high
    ₹ 673.70 ₹ 703.00
    ₹ 677.50
    52 week low 52 week high
    ₹ 409.30 ₹ 714.70
    ₹ 677.50
    Open Price ₹ 687.40
    Prev. Close ₹ 687.30
    Volume (Shares) 151263.00
    Total traded value ₹ 1024.80
    Upper Circuit ₹ 756.00
    Lower Circuit ₹ 618.60
    info

    Investment Returns

    Over 1 Month 12.01% Over 3 Months 33.63% Over 6 Months 60.30% Over 1 Year 27.89%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    AKUMS DRUGS AND PHARMA L fundamentals


    • Market cap (Cr) 10,638.30
    • P/E Ratio (TTM) 96.53
    • Beta 0.97
    • Book Value / share 154.28
    • Return on equity 4.72%
    • EPS (TTM) 7.40
    • Dividend yield 0.43%
    • Net profit/quarter (Cr) 15.20
    info icon alternate text
    • Market cap (Cr) 10,648.50
    • P/E Ratio (TTM) 96.53
    • Beta 0.90
    • Book Value / share 154.28
    • Return on equity 4.72%
    • EPS (TTM) 7.40
    • Dividend yield 0.43%
    • Net profit/quarter (Cr) 15.20
    info icon alternate text

    AKUMS DRUGS AND PHARMA L Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 338.37
    Operating Expense 341.59
    Net Profit 15.20
    Net Profit Margin (%) 4.49
    Earnings Per Share (EPS) 0.99
    EBITDA 36.80
    Effective Tax Rate (%) 30.24
    Particulars DEC 2025 (Values in Cr)
    Revenue 368.61
    Operating Expense 358.53
    Net Profit 28.11
    Net Profit Margin (%) 7.62
    Earnings Per Share (EPS) 1.84
    EBITDA 50.48
    Effective Tax Rate (%) 21.60
    Particulars SEP 2025 (Values in Cr)
    Revenue 309.32
    Operating Expense 305.19
    Net Profit 23.46
    Net Profit Margin (%) 7.58
    Earnings Per Share (EPS) 1.53
    EBITDA 43.97
    Effective Tax Rate (%) 24.80
    Particulars JUN 2025 (Values in Cr)
    Revenue 332.44
    Operating Expense 301.49
    Net Profit 44.87
    Net Profit Margin (%) 13.49
    Earnings Per Share (EPS) 2.93
    EBITDA 72.67
    Effective Tax Rate (%) 24.60
    Particulars MAR 2025 (Values in Cr)
    Revenue 328.75
    Operating Expense 323.75
    Net Profit 27.59
    Net Profit Margin (%) 8.39
    Earnings Per Share (EPS) 1.80
    EBITDA 49.78
    Effective Tax Rate (%) 25.55
    Particulars MAR 2026 (Values in Cr)
    Revenue 1348.74
    Operating Expense 1306.82
    Net Profit 111.64
    Net Profit Margin (%) 8.27
    Earnings Per Share (EPS) 7.29
    EBITDA 203.91
    Effective Tax Rate (%) 24.75
    Particulars MAR 2025 (Values in Cr)
    Revenue 1311.78
    Operating Expense 1228.13
    Net Profit 161.00
    Net Profit Margin (%) 12.27
    Earnings Per Share (EPS) 10.76
    EBITDA 262.70
    Effective Tax Rate (%) 22.53
    Particulars MAR 2024 (Values in Cr)
    Revenue 1444.12
    Operating Expense 1621.78
    Net Profit -165.45
    Net Profit Margin (%) -11.45
    Earnings Per Share (EPS) -11.56
    EBITDA -51.93
    Effective Tax Rate (%) -60.74
    Particulars MAR 2023 (Values in Cr)
    Revenue 1286.83
    Operating Expense 1088.13
    Net Profit 125.43
    Net Profit Margin (%) 9.74
    Earnings Per Share (EPS) 8.77
    EBITDA 193.50
    Effective Tax Rate (%) 16.55
    Particulars MAR 2022 (Values in Cr)
    Revenue 1162.06
    Operating Expense 1555.51
    Net Profit -381.78
    Net Profit Margin (%) -32.85
    Earnings Per Share (EPS) -53.33
    EBITDA -303.57
    Effective Tax Rate (%) -13.97
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 216.41
    ROE % 8.06
    ROCE % 12.53
    Total Debt to Total Equity 0.04
    EBITDA Margin 14.47
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 199.01
    ROE % 18.30
    ROCE % 12.86
    Total Debt to Total Equity 0.17
    EBITDA Margin 12.95
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 49.59
    ROE % -2.22
    ROCE % 1.24
    Total Debt to Total Equity 0.83
    EBITDA Margin 3.76
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 50.13
    ROE % 19.46
    ROCE % 11.73
    Total Debt to Total Equity 0.76
    EBITDA Margin 10.32
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 86.95
    ROE % -33.30
    ROCE % -9.43
    Total Debt to Total Equity 0.33
    EBITDA Margin -2.23
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 158.56
    ROE % 4.72
    ROCE % 6.48
    Total Debt to Total Equity 0.02
    EBITDA Margin 15.12
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 150.57
    ROE % 13.15
    ROCE % 10.70
    Total Debt to Total Equity 0.13
    EBITDA Margin 20.03
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 10.06
    ROE % -69.16
    ROCE % -3.92
    Total Debt to Total Equity 0.91
    EBITDA Margin -2.23
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 21.77
    ROE % 92.77
    ROCE % 21.17
    Total Debt to Total Equity 0.57
    EBITDA Margin 26.27
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 25.94
    ROE % -101.46
    ROCE % -25.83
    Total Debt to Total Equity 0.22
    EBITDA Margin -26.12
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 1680.59
    Total Assets 5446.96
    Total Liabilities 5446.96
    Total Equity 3331.12
    Share Outstanding 15
    Price to Book Ratio 2.94
    Return on Assets (%) 4.68
    Return on Capital (%) 7.5
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 576.45
    Total Assets 4113.44
    Total Liabilities 4113.44
    Total Equity 3063.61
    Share Outstanding 15
    Price to Book Ratio 3.15
    Return on Assets (%) 8.22
    Return on Capital (%) 10.99
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 277.05
    Total Assets 3516.36
    Total Liabilities 3516.36
    Total Equity 720.48
    Share Outstanding 14
    Price to Book Ratio 0.00
    Return on Assets (%) -0.11
    Return on Capital (%) -0.33
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 149.98
    Total Assets 3266.52
    Total Liabilities 3266.52
    Total Equity 723.37
    Share Outstanding 14
    Price to Book Ratio 0.00
    Return on Assets (%) 2.90
    Return on Capital (%) 7.53
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 102.84
    Total Assets 3069.04
    Total Liabilities 3069.04
    Total Equity 625.17
    Share Outstanding 7
    Price to Book Ratio 0.00
    Return on Assets (%) -8.22
    Return on Capital (%) -25.69
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 770.94
    Total Assets 2812.47
    Total Liabilities 2812.47
    Total Equity 2427.56
    Share Outstanding 15
    Price to Book Ratio 2.94
    Return on Assets (%) 3.96
    Return on Capital (%) 4.57
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 356.11
    Total Assets 2684.91
    Total Liabilities 2684.91
    Total Equity 2305.24
    Share Outstanding 15
    Price to Book Ratio 3.15
    Return on Assets (%) 5.99
    Return on Capital (%) 6.97
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 73.31
    Total Assets 2095.42
    Total Liabilities 2095.42
    Total Equity 143.87
    Share Outstanding 14
    Price to Book Ratio 0.00
    Return on Assets (%) -7.89
    Return on Capital (%) -44.7
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 8.84
    Total Assets 1894.20
    Total Liabilities 1894.20
    Total Equity 311.50
    Share Outstanding 14
    Price to Book Ratio 0.00
    Return on Assets (%) 6.62
    Return on Capital (%) 27.44
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 25.73
    Total Assets 1813.94
    Total Liabilities 1813.94
    Total Equity 185.53
    Share Outstanding 7
    Price to Book Ratio 0.00
    Return on Assets (%) -21.04
    Return on Capital (%) -124.1
    Particulars MAR 2026 (Values in Cr)
    Net Income 382.10
    Cash from Operations 1268.57
    Cash from Investing -930.26
    Cash from Financing 33.88
    Net change in Cash 284.81
    Free Cash Flow 1499.09
    Particulars MAR 2025 (Values in Cr)
    Net Income 345.25
    Cash from Operations 546.43
    Cash from Investing -547.84
    Cash from Financing 72.78
    Net change in Cash -9.85
    Free Cash Flow 818.74
    Particulars MAR 2024 (Values in Cr)
    Net Income -45.27
    Cash from Operations 560.67
    Cash from Investing -330.41
    Cash from Financing -108.02
    Net change in Cash 59.82
    Free Cash Flow 872.08
    Particulars MAR 2023 (Values in Cr)
    Net Income 150.29
    Cash from Operations 273.69
    Cash from Investing -304.70
    Cash from Financing 124.54
    Net change in Cash -3.53
    Free Cash Flow 602.48
    Particulars MAR 2022 (Values in Cr)
    Net Income -193.19
    Cash from Operations 86.67
    Cash from Investing -234.82
    Cash from Financing 236.04
    Net change in Cash 33.07
    Free Cash Flow 344.25
    Particulars MAR 2026 (Values in Cr)
    Net Income 148.36
    Cash from Operations 33.69
    Cash from Investing -24.96
    Cash from Financing -2.99
    Net change in Cash -30.10
    Free Cash Flow 155.76
    Particulars MAR 2025 (Values in Cr)
    Net Income 207.83
    Cash from Operations 139.87
    Cash from Investing -458.84
    Cash from Financing 375.37
    Net change in Cash 7.53
    Free Cash Flow 235.48
    Particulars MAR 2024 (Values in Cr)
    Net Income -102.93
    Cash from Operations 284.19
    Cash from Investing -165.44
    Cash from Financing -20.74
    Net change in Cash 61.72
    Free Cash Flow 356.05
    Particulars MAR 2023 (Values in Cr)
    Net Income 150.31
    Cash from Operations 35.57
    Cash from Investing -202.16
    Cash from Financing 89.90
    Net change in Cash -18.25
    Free Cash Flow 151.83
    Particulars MAR 2022 (Values in Cr)
    Net Income -334.97
    Cash from Operations 235.50
    Cash from Investing -297.95
    Cash from Financing 94.98
    Net change in Cash 25.34
    Free Cash Flow 265.79
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 32.45 13.46 1.57 248.68 23.12 38.85
    BLISS GVS PHARMA LTD 463.55 37.26 4.12 4916.24 118.35 552.90
    CIPLA LTD. 1410.90 31.85 3.31 113978.90 1165.55 1672.20
    FERMENTA BIOTECH LTD. 432.60 20.23 3.13 1273.18 256.40 480.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 32.45 22.69 4.18 248.68 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 510.50 22.88 3.98 1475.89 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8000.10 104.55 22.91 20000.25 7630.00 9850.00
    BLISS GVS PHARMA LTD 463.55 50.11 4.25 4916.24 118.35 552.90

    AKUMS DRUGS AND PHARMA L shareholding pattern

    Holding
    9.39%
    75.26%
    1.9%
    13.43%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    AKUMS DRUGS AND PHARMA L Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    675.90 -1.65 redarrow
    red-green-graph indicator
    6 Bearish
    10 Bullish
    • 5 Days 689.10
    • 26 Days 653.80
    • 10 Days 682.60
    • 50 Days 618.50
    • 12 Days 679.20
    • 100 Days 573.60
    • 20 Days 664.40
    • 200 Days 543.80
    694.65 PIVOT
    First Support 688.20 First Resistance 702.35 Second Support 680.50 Second Resistance 708.80 Third Support 674.05 Third Resistance 716.50
    RSI 63.25 ADX 58.26 MACD 25.40 Williams % R -29.88 Commodity Channel Index (CCI) 59.61
    Date 2026-07-24 Week 152367.00 Same Day 61228.00 Month 177734.00
    1 Year 0.97 3 Year 1.12
    Over 1 Month
    12.01% down
    Over 1 Year
    27.89% down
    Over 3 Months
    33.63% down
    Over 3 Years
    0.00% down
    Over 6 Months
    60.30% down
    Over 5 Years
    0.00% down

    AKUMS DRUGS AND PHARMA L Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    03 Jul 2026 2.0 Special 03 Jul 2026 Equity shares
    03 Jul 2026 1.0 Final 03 Jul 2026 Equity shares
    Dividend date Dividend amount Dividend type Record date Instrument type
    03 Jul 2026 2.0 Special 03 Jul 2026 Equity shares
    03 Jul 2026 1.0 Final 03 Jul 2026 Equity shares

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Akums Drugs & Pharmaceuticals Ltd?

    Answer Field

    Akums Drugs & Pharmaceuticals Ltd share price is for NSE ₹ 674.65 & for BSE ₹ 675.40 as on Jul 27 2026 03:13 PM.

    What is the Market Cap of Akums Drugs & Pharmaceuticals Ltd Share?

    Answer Field

    The market cap of Akums Drugs & Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 27 2026 03:13 PM.

    What is the 52 Week High and Low of Akums Drugs & Pharmaceuticals Ltd?

    Answer Field

    The 52 Week High and Low of Akums Drugs & Pharmaceuticals Ltd for NSE is ₹ 714.70 and ₹ 409.30 and for BSE is ₹ 713.80 and ₹ 410.10.

    What is 1 year return for Akums Drugs & Pharmaceuticals Ltd?

    Answer Field

    The 1 year returns on the stock has been 27.89%.

    What is the P/E Ratio of Akums Drugs & Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 27 2026 03:13 PM the price-to-earnings (PE) ratio for Akums Drugs & Pharmaceuticals Ltd share is 96.53.

    What is the PB ratio of Akums Drugs & Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 27 2026 03:13 PM, the price-to-book (PB) ratio for Akums Drugs & Pharmaceuticals Ltd share is 154.28.

    How to Buy Akums Drugs & Pharmaceuticals Ltd Share?

    Answer Field

    You can trade in Akums Drugs & Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Akums Drugs & Pharmaceuticals Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Akums Drugs & Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Akums Drugs & Pharmaceuticals Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |